BETA


2019/2925(RSP) Resolution on the draft Commission implementing regulation amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil, mancozeb, mecoprop-P, mepiquat, metiram, oxamyl and pyraclostrobin

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead ENVI METZ Tilly (icon: Verts/ALE Verts/ALE), HAZEKAMP Anja (icon: GUE/NGL GUE/NGL), EVI Eleonora (icon: NA NA)
Lead committee dossier:
Legal Basis:
RoP 112-p2

Events

2019/12/18
   EP - Motion for a resolution
Documents
2019/12/18
   EP - Decision by Parliament, 1st reading/single reading
Details

The European Parliament adopted by 443 votes to 216, with 33 abstentions, a resolution objecting to the draft Commission implementing regulation amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil, mancozeb, mecoprop-P, mepiquat, metiram, oxamyl and pyraclostrobin.

Parliament considered that the draft Commission implementing regulation exceeds the implementing powers provided for in Regulation (EC) No 1107/2009 and that it does not respect the precautionary principle. It stated that the decision to extend the approval periods of dimoxystrobin and mancozeb is not in line with the safety criteria laid down in Regulation (EC) No 1107/2009, and is based neither on evidence that those substances can safely be used, nor on a proven urgent need for them in food production in the Union.

In support of its objection, Parliament stated that mancozeb is very toxic to aquatic life and is suspected of damaging the human foetus and may cause allergic skin reactions. Exposure to mancozeb is also linked to an increase in the risk of Parkinson’s disease amongst farmers and other people in rural areas in the Netherlands and France.

Dimoxystrobin is considered as having endocrine-disrupting properties that may cause adverse effects in humans.

Members also considered it is unacceptable that a substance which is known to meet the cut-off criteria for active substances that are mutagenic, carcinogenic and/or toxic for reproduction or that have endocrine-disrupting properties, which are set to protect human and environmental health, continues to be allowed for use in the Union, putting public and environmental health at risk.

In view of these elements, Parliament called on the Commission to:

withdraw its draft implementing regulation and to submit a new draft to the Committee that takes into account the scientific evidence on the harmful properties of all the substances concerned, especially those of dimoxystrobin and mancozeb; present proposals for non-renewal of dimoxystrobin and mancozeb in the next meeting of the Standing Committee on Plants, Animals, Food and Feed; present draft implementing regulations to extend the approval periods only of substances in relation to which the current state of science is not expected to lead to a Commission proposal for non-renewal of the approval of the active substance concerned; withdraw the approvals relating to substances, if proof or reasonable doubts exist that they will not meet the safety criteria laid down in Regulation (EC) No 1107/2009.

Member States should ensure the proper and timely reassessment of the approvals of the active substances for which they are the reporting Member States, and to ensure that the current delays are solved effectively as soon as possible.

Documents
2019/12/18
   EP - End of procedure in Parliament
2019/11/19
   EP - METZ Tilly (Verts/ALE) appointed as rapporteur in ENVI
2019/11/19
   EP - HAZEKAMP Anja (GUE/NGL) appointed as rapporteur in ENVI
2019/11/19
   EP - EVI Eleonora (NA) appointed as rapporteur in ENVI

Documents

Votes

B9-0230/2019 - Résolution

2019/12/18 Outcome: +: 443, -: 216, 0: 33
FR IT GB ES PT BE SK HR DE CY BG DK RO SE LV EE LU EL IE LT MT NL FI SI HU AT CZ PL
Total
66
67
59
48
20
21
13
10
90
6
17
13
29
18
8
6
5
19
10
10
6
26
12
8
17
18
21
49
icon: S&D S&D
145

Cyprus S&D

2

Latvia S&D

2

Estonia S&D

2

Luxembourg S&D

For (1)

1

Greece S&D

1

Lithuania S&D

2

Finland S&D

1

Slovenia S&D

2
icon: Verts/ALE Verts/ALE
70

Spain Verts/ALE

2

Portugal Verts/ALE

1

Belgium Verts/ALE

3

Denmark Verts/ALE

2

Sweden Verts/ALE

2

Latvia Verts/ALE

1

Luxembourg Verts/ALE

For (1)

1

Ireland Verts/ALE

2

Lithuania Verts/ALE

2

Netherlands Verts/ALE

3

Finland Verts/ALE

2

Austria Verts/ALE

2

Czechia Verts/ALE

3
icon: Renew Renew
105

Belgium Renew

Against (1)

4

Slovakia Renew

2

Croatia Renew

For (1)

1

Sweden Renew

For (1)

3

Latvia Renew

For (1)

1

Estonia Renew

3

Luxembourg Renew

2

Ireland Renew

For (1)

1

Lithuania Renew

2

Finland Renew

3

Slovenia Renew

2

Hungary Renew

2

Austria Renew

Abstain (1)

1
icon: GUE/NGL GUE/NGL
37

Belgium GUE/NGL

For (1)

1

Cyprus GUE/NGL

2

Denmark GUE/NGL

1

Ireland GUE/NGL

3

Netherlands GUE/NGL

For (1)

1

Finland GUE/NGL

For (1)

1

Czechia GUE/NGL

1
icon: ID ID
69

Denmark ID

Against (1)

1

Estonia ID

Against (1)

1

Finland ID

2

Austria ID

3

Czechia ID

2
icon: NI NI
44

Slovakia NI

For (1)

Abstain (1)

2

Croatia NI

1

Germany NI

1

Hungary NI

1
icon: ECR ECR
58

United Kingdom ECR

Against (1)

1

Slovakia ECR

Against (1)

2

Croatia ECR

Against (1)

1

Germany ECR

For (1)

1

Bulgaria ECR

2

Latvia ECR

2

Lithuania ECR

Against (1)

1

Netherlands ECR

4
icon: PPE PPE
164

Belgium PPE

Against (1)

4
2

Denmark PPE

For (1)

1

Latvia PPE

For (1)

Against (1)

2

Luxembourg PPE

Abstain (1)

1

Malta PPE

2

Finland PPE

3

Slovenia PPE

4

History

(these mark the time of scraping, not the official date of the change)

docs/1
date
2019-12-18T00:00:00
docs
url: http://www.europarl.europa.eu/doceo/document/TA-9-2019-0099_EN.html title: T9-0099/2019
type
Text adopted by Parliament, single reading
body
EP
events/0/summary
  • The European Parliament adopted by 443 votes to 216, with 33 abstentions, a resolution objecting to the draft Commission implementing regulation amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil, mancozeb, mecoprop-P, mepiquat, metiram, oxamyl and pyraclostrobin.
  • Parliament considered that the draft Commission implementing regulation exceeds the implementing powers provided for in Regulation (EC) No 1107/2009 and that it does not respect the precautionary principle. It stated that the decision to extend the approval periods of dimoxystrobin and mancozeb is not in line with the safety criteria laid down in Regulation (EC) No 1107/2009, and is based neither on evidence that those substances can safely be used, nor on a proven urgent need for them in food production in the Union.
  • In support of its objection, Parliament stated that mancozeb is very toxic to aquatic life and is suspected of damaging the human foetus and may cause allergic skin reactions. Exposure to mancozeb is also linked to an increase in the risk of Parkinson’s disease amongst farmers and other people in rural areas in the Netherlands and France.
  • Dimoxystrobin is considered as having endocrine-disrupting properties that may cause adverse effects in humans.
  • Members also considered it is unacceptable that a substance which is known to meet the cut-off criteria for active substances that are mutagenic, carcinogenic and/or toxic for reproduction or that have endocrine-disrupting properties, which are set to protect human and environmental health, continues to be allowed for use in the Union, putting public and environmental health at risk.
  • In view of these elements, Parliament called on the Commission to:
  • withdraw its draft implementing regulation and to submit a new draft to the Committee that takes into account the scientific evidence on the harmful properties of all the substances concerned, especially those of dimoxystrobin and mancozeb; present proposals for non-renewal of dimoxystrobin and mancozeb in the next meeting of the Standing Committee on Plants, Animals, Food and Feed; present draft implementing regulations to extend the approval periods only of substances in relation to which the current state of science is not expected to lead to a Commission proposal for non-renewal of the approval of the active substance concerned; withdraw the approvals relating to substances, if proof or reasonable doubts exist that they will not meet the safety criteria laid down in Regulation (EC) No 1107/2009.
  • Member States should ensure the proper and timely reassessment of the approvals of the active substances for which they are the reporting Member States, and to ensure that the current delays are solved effectively as soon as possible.